Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in adolescents in Taiwan: A double-blind, randomized, placebo-controlled phase 2 trial
Luke Tzu-Chi Liu, Cheng-Hsun Chiu, Nan-Chang Chiu, Boon-Fatt Tan, Chien-Yu Lin, Hao-Yuan Cheng, Meei-Yun Lin, View ORCID ProfileChia-En Lien, Charles Chen, Li-Min Huang
doi: https://doi.org/10.1101/2022.03.14.22272325
Luke Tzu-Chi Liu
1Medigen Vaccine Biologics Corporation, Taipei, Taiwan
Cheng-Hsun Chiu
2Department of Pediatrics, Chang Gung Children’s Hospital, Chang Gung University College of Medicine, Taoyuan City, Taiwan
Nan-Chang Chiu
3Department of Pediatrics, MacKay Children’s Hospital, Taipei City, Taiwan
Boon-Fatt Tan
4Department of Pediatrics, National Taiwan University Hospital Hsinchu Branch, Hsinchu County, Taiwan
Chien-Yu Lin
5Department of Pediatrics, Hsinchu MacKay Memorial Hospital, Hsinchu City, Taiwan
Hao-Yuan Cheng
1Medigen Vaccine Biologics Corporation, Taipei, Taiwan
Meei-Yun Lin
1Medigen Vaccine Biologics Corporation, Taipei, Taiwan
Chia-En Lien
1Medigen Vaccine Biologics Corporation, Taipei, Taiwan
6Institute of Public Health, National Yang-Ming Chiao Tung University, Taipei City, Taiwan
Charles Chen
1Medigen Vaccine Biologics Corporation, Taipei, Taiwan
Li-Min Huang
7Department of Pediatrics, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
- Supplemental figure and tables[supplements/272325_file05.docx]
Posted March 15, 2022.
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in adolescents in Taiwan: A double-blind, randomized, placebo-controlled phase 2 trial
Luke Tzu-Chi Liu, Cheng-Hsun Chiu, Nan-Chang Chiu, Boon-Fatt Tan, Chien-Yu Lin, Hao-Yuan Cheng, Meei-Yun Lin, Chia-En Lien, Charles Chen, Li-Min Huang
medRxiv 2022.03.14.22272325; doi: https://doi.org/10.1101/2022.03.14.22272325
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in adolescents in Taiwan: A double-blind, randomized, placebo-controlled phase 2 trial
Luke Tzu-Chi Liu, Cheng-Hsun Chiu, Nan-Chang Chiu, Boon-Fatt Tan, Chien-Yu Lin, Hao-Yuan Cheng, Meei-Yun Lin, Chia-En Lien, Charles Chen, Li-Min Huang
medRxiv 2022.03.14.22272325; doi: https://doi.org/10.1101/2022.03.14.22272325
Subject Area
Subject Areas
- Addiction Medicine (336)
- Allergy and Immunology (662)
- Anesthesia (177)
- Cardiovascular Medicine (2588)
- Dermatology (218)
- Emergency Medicine (390)
- Epidemiology (12117)
- Forensic Medicine (10)
- Gastroenterology (751)
- Genetic and Genomic Medicine (4017)
- Geriatric Medicine (378)
- Health Economics (670)
- Health Informatics (2595)
- Health Policy (994)
- Hematology (357)
- HIV/AIDS (829)
- Medical Education (397)
- Medical Ethics (107)
- Nephrology (425)
- Neurology (3787)
- Nursing (207)
- Nutrition (560)
- Oncology (1975)
- Ophthalmology (574)
- Orthopedics (233)
- Otolaryngology (301)
- Pain Medicine (248)
- Palliative Medicine (72)
- Pathology (469)
- Pediatrics (1095)
- Primary Care Research (442)
- Public and Global Health (6458)
- Radiology and Imaging (1372)
- Respiratory Medicine (866)
- Rheumatology (395)
- Sports Medicine (336)
- Surgery (434)
- Toxicology (51)
- Transplantation (185)
- Urology (165)